1. Home
  2. ACOG vs ANTX Comparison

ACOG vs ANTX Comparison

Compare ACOG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$8.80

Market Cap

193.6M

Sector

N/A

ML Signal

N/A

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

N/A

Current Price

$5.36

Market Cap

172.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACOG
ANTX
Founded
2000
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.6M
172.9M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
ACOG
ANTX
Price
$8.80
$5.36
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$16.00
$2.00
AVG Volume (30 Days)
153.2K
198.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
41.58
32.56
EPS
N/A
N/A
Revenue
$10,220,275.00
N/A
Revenue This Year
$139.22
N/A
Revenue Next Year
$134.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$1.00
52 Week High
$10.14
$7.19

Technical Indicators

Market Signals
Indicator
ACOG
ANTX
Relative Strength Index (RSI) 44.47 43.50
Support Level $7.50 $3.91
Resistance Level $9.04 $5.51
Average True Range (ATR) 0.51 0.34
MACD -0.12 -0.07
Stochastic Oscillator 13.91 13.68

Price Performance

Historical Comparison
ACOG
ANTX

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: